ArticleDrug delivery and translational research2021
Docetaxel-loaded D-α-tocopheryl polyethylene glycol-1000 succinate liposomes improve lung cancer chemotherapy and reverse multidrug resistance.
Article in Drug delivery and translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 43 citations in OpenAlex.
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Article
- Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine.Discover oncology · 2024Review
- Advanced Delivery Strategies of Nintedanib for Lung Disorders and Beyond: A Comprehensive Review.AAPS PharmSciTech · 2024Review
- Review
- Role of natural P-gp inhibitor in the effective delivery for chemotherapeutic agents.Journal of cancer research and clinical oncology · 2023Review
- TPGS Decorated Liposomes as Multifunctional Nano-Delivery Systems.Pharmaceutical research · 2023Review
- Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- A novel saponin liposomes based on the couplet medicines ofDrug delivery · 2022Article
- Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.Journal of nanobiotechnology · 2022Review
- Nicotine-induced miR-21-3p promotes chemoresistance in lung cancer by negatively regulating FOXO3a.Oncology letters · 2022Article
- Article
- Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, D-alpha-tocopheryl polyethylene glycol-1000 succinate (TPGS)-coated docetaxel-loaded liposomes were developed to reverse multidrug resistance (MDR) and enhance lung cancer therapy. Evaluations were performed using human lung cancer A549 and resistant A549/DDP cells. The reversal multidrug resistant effect was assessed by P-gp inhibition assay, cytotoxicity, cellular uptake, and apoptosis assay. The tumor xenograft model was built by subcutaneous injection of A549/DDP cells in the right dorsal area of nude mice. The tumor volumes and body weights were measured every other day. The TPGS-coated liposomes showed a concentration- and time-dependent cytotoxicity and significantly enhanced the cytotoxicity of docetaxel in A549/DDP cells. Confocal laser scanning images indicated that higher concentrations of coumarin-6 were successfully delivered into the cytoplasm, and the TPGS-coated liposomes enhanced intracellular drug accumulation by inhibiting overexpressed P-glycoprotein. The TPGS-coated liposomes were shown to induce apoptosis. Furthermore, in vivo anti-tumor studies revealed that TPGS-coated docetaxel-loaded liposomes had outstanding anti-tumor efficacy in an A549/DDP xenograft model. The TPGS-coated liposomes, compared with PEG-coated liposomes, showed significant advantages in vitro and in vivo. The TPGS-coated liposomes were able to reverse MDR and enhance lung cancer therapy. Graphical abstract .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.